Abemaciclib (Verzenios®). HTA ID: 22020

Assessment Status NCPE Assessment Process complete
HTA ID 22020
Drug Abemaciclib
Brand Verzenios®
Indication in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative, node positive early breast cancer at high risk of recurrence.
Assessment Process
Rapid review commissioned 11/04/2022
Rapid review completed 06/05/2022
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of abemaciclib compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 26/05/2022
Pre-submission consultation with Applicant 26/07/2022
Full submission received from Applicant 28/03/2023
Preliminary review sent to Applicant 06/04/2023
NCPE assessment re-commenced 10/05/2023
Follow-up to preliminary review sent to Applicant 21/06/2023
NCPE assessment re-commenced 29/06/2023
Factual accuracy sent to Applicant 18/08/2023
NCPE assessment re-commenced 25/08/2023
NCPE assessment completed 19/09/2023
NCPE assessment outcome The NCPE recommends that abemaciclib (Verzenios®) be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*.

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

The HSE has approved reimbursement following confidential price negotiations June 2024.